Products for Research Use Only
RegisterLogin

Moxonidine-d7

CAT: 0804-HY-B0374S1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0374S1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Moxonidine-d7 is deuterated labeled Moxonidine. Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I1-R) agonist. Moxonidine activates imidazoline I1 receptors and α2 adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis[1][2][3][4][5][6][7].
Product Name Alternative
BDF5895-d7
UNSPSC
12352005
Target
Adrenergic Receptor; Imidazoline Receptor; Isotope-Labeled Compounds; LDLR
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease; Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
CC1=NC(OC([2H])([2H])[2H])=C(NC2=NC([2H])([2H])C([2H])([2H])N2)C(Cl)=N1
Molecular Formula
C9H5D7ClN5O
Molecular Weight
248.72
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Aceros H, et al. Moxonidine modulates cytokine signalling and effects on cardiac cell viability. Eur J Pharmacol. 2014 Oct 5;740:168-82.|[3]Wang Y, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023 Feb 14;24 (4) :3857.|[4]Kim YH, et al. Modulation of N-type Ca²⁺ currents by moxonidine via imidazoline I₁ receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011 Jun 17;409 (4) :645-50. |[5]Zhu QM, et al. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126 (6) :1522-30.|[6]Van Kerckhoven R, et al. Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model. Eur J Pharmacol. 2000 May 26;397 (1) :113-20. |[7]Nurminen ML, et al. Effect of moxonidine on blood pressure and sympathetic tone in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 27;362 (1) :61-7. |[8]Tsutsui H, et al. Moxonidine prevents ischemia/reperfusion-induced renal injury in rats. Eur J Pharmacol. 2009 Jan 28;603 (1-3) :73-8.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Related Products

CatalogName
HY-B0374-01Moxonidine
HY-B0374S2Moxonidine-d3
HY-B0374S-01Moxonidine-d4
HY-B0374R-01Moxonidine (Standard)
HY-B0374A-01Moxonidine (hydrochloride)
HY-W767936Moxonidine-13C, d3
HY-B0374AR-01Moxonidine (hydrochloride) (Standard)
HY-B0374ASMoxonidine-13C, d3 (hydrochloride)
HY-B0573S1-01Propranolol-d7 (ring-d7)
HY-W745140Hydroxyatenolol-d7

Alternative Products

CatalogName
A4080-5.1Moxonidine

Popular Products